Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8TDX

TRNM-b.01 in complex with HIV Env fusion peptide

Summary for 8TDX
Entry DOI10.2210/pdb8tdx/pdb
DescriptorTRNM-b.01 Fab Heavy Chain, TRNM-b.01 Fab Light Chain, Env Fusion Peptide, ... (4 entities in total)
Functional Keywordshiv-1, fusion peptide, antibody, fab, immune system
Biological sourceMacaca mulatta (Rhesus monkey)
More
Total number of polymer chains6
Total formula weight97236.42
Authors
Olia, A.S.,Kwong, P.D. (deposition date: 2023-07-05, release date: 2024-07-10, Last modification date: 2025-01-15)
Primary citationWang, H.,Cheng, C.,Dal Santo, J.L.,Shen, C.H.,Bylund, T.,Henry, A.R.,Howe, C.A.,Hwang, J.,Morano, N.C.,Morris, D.J.,Pletnev, S.,Roark, R.S.,Zhou, T.,Hansen, B.T.,Hoyt, F.H.,Johnston, T.S.,Wang, S.,Zhang, B.,Ambrozak, D.R.,Becker, J.E.,Bender, M.F.,Changela, A.,Chaudhary, R.,Corcoran, M.,Corrigan, A.R.,Foulds, K.E.,Guo, Y.,Lee, M.,Li, Y.,Lin, B.C.,Liu, T.,Louder, M.K.,Mandolesi, M.,Mason, R.D.,McKee, K.,Nair, V.,O'Dell, S.,Olia, A.S.,Ou, L.,Pegu, A.,Raju, N.,Rawi, R.,Roberts-Torres, J.,Sarfo, E.K.,Sastry, M.,Schaub, A.J.,Schmidt, S.D.,Schramm, C.A.,Schwartz, C.L.,Smith, S.C.,Stephens, T.,Stuckey, J.,Teng, I.T.,Todd, J.P.,Tsybovsky, Y.,Van Wazer, D.J.,Wang, S.,Doria-Rose, N.A.,Fischer, E.R.,Georgiev, I.S.,Karlsson Hedestam, G.B.,Sheng, Z.,Woodward, R.A.,Douek, D.C.,Koup, R.A.,Pierson, T.C.,Shapiro, L.,Shaw, G.M.,Mascola, J.R.,Kwong, P.D.
Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques.
Cell, 187:7214-7231.e23, 2024
Cited by
PubMed Abstract: An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection by simian-human immunodeficiency virus (SHIV). In four macaques with vaccine-induced neutralizing responses, SHIV infection boosted plasma neutralization to 45%-77% breadth (geometric mean 50% inhibitory dilution [ID] ∼100) on a 208-strain panel. Molecular dissection of these responses by antibody isolation and cryo-electron microscopy (cryo-EM) structure determination revealed 15 of 16 antibody lineages with cross-clade neutralization to be directed toward the fusion-peptide site of vulnerability. In each macaque, isolated antibodies from memory B cells recapitulated the plasma-neutralizing response, with fusion-peptide-binding antibodies reaching breadths of 40%-60% (50% inhibitory concentration [IC] < 50 μg/mL) and total lineage-concentrations estimates of 50-200 μg/mL. Longitudinal mapping indicated that these responses arose prior to SHIV infection. Collectively, these results provide in vivo molecular examples for one to a few B cell lineages affording potent, broadly neutralizing plasma responses.
PubMed: 39471811
DOI: 10.1016/j.cell.2024.10.003
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.09 Å)
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon